Atreca (BCEL) to Release Quarterly Earnings on Wednesday

Atreca (NASDAQ:BCELGet Free Report) is set to issue its quarterly earnings data on Wednesday, March 27th.

Atreca Stock Performance

BCEL opened at $0.07 on Tuesday. The company has a 50-day moving average of $0.25 and a 200-day moving average of $0.24. The company has a market capitalization of $2.81 million, a P/E ratio of -0.03 and a beta of 1.17. Atreca has a 1-year low of $0.05 and a 1-year high of $1.35.

Institutional Investors Weigh In On Atreca

Institutional investors have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Atreca in the 1st quarter worth approximately $41,000. IHT Wealth Management LLC acquired a new stake in Atreca during the first quarter valued at approximately $41,000. Advisor Group Holdings Inc. lifted its stake in Atreca by 111.8% during the first quarter. Advisor Group Holdings Inc. now owns 16,573 shares of the company’s stock valued at $52,000 after purchasing an additional 8,750 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in Atreca during the first quarter valued at approximately $26,000. Finally, Virtu Financial LLC raised its holdings in shares of Atreca by 248.8% during the first quarter. Virtu Financial LLC now owns 45,574 shares of the company’s stock valued at $144,000 after acquiring an additional 32,508 shares during the period. Institutional investors own 37.47% of the company’s stock.

Atreca Company Profile

(Get Free Report)

Atreca, Inc, a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Recommended Stories

Earnings History for Atreca (NASDAQ:BCEL)

Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.